Prescription medicine
Nifedipine Brand names: Procardia
Nifedipine (Procardia) is a prescription medicine with an FDA approval on record since 1981. FDA's NDC Directory lists it from 32 generic labelers, and pharmacies paid $0.130 per nifedipine ER 30 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the nifedipine FDA label on DailyMed (effective December 24, 2024, Aurobindo Pharma Limited); the NDA 18482 record on Drugs@FDA; every nifedipine label on DailyMed.
Highlights of the record
FDA label of December 24, 2024; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageNifedipine extended-release tablets are indicated for the treatment of hypertension.
Forms and strengths
- 10 mg
- 20 mg
- 30 mg
- 60 mg
- 90 mg
Extended-release tablet; film-coated extended-release tablet; capsule.
On the market
- Earliest approval on file
- December 31, 1981 Procardia, Pfizer; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 32 first April 28, 1989; 19 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 33 of which 32 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $0.130 per tablet Nifedipine ER 30 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 7 since 2013 0 Class I among all firms' recalls; latest July 2, 2021; 3 more by firms not listed as its makers
- FAERS reports
- 41,059 through July 30, 2026
What is nifedipine used for?
From the label: indications and usageNifedipine extended-release tablets are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
Conditions named in the indications of nifedipine's FDA labels, with every medicine labeled for each:
From other nifedipine labelsHigh blood pressure: INDICATION AND USAGE Nifedipine extended-release tablets are indicated for the treatment of hypertension.
Angina: INDICATIONS AND USAGE I. Vasospastic Angina Nifedipine is indicated for the management of vasospastic angina confirmed by any of the following criteria:
FDA pharmacologic class: Dihydropyridine Calcium Channel Blocker.
Source: FDA drug label (Nifedipine), Aurobindo Pharma Limited, effective December 24, 2024 (SPL set eb70b7ff-f9f0-41d0-901a-f4c04ae9ed46), via openFDA; the full label on DailyMed
Is there a generic for nifedipine (Procardia)?
The FDA approved the first generic nifedipine on April 28, 1989. 32 generic applications are approved; 19 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists nifedipine from 32 labelers under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1981 earliest approval on file
- 1989 first generic approved
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for nifedipine (Procardia)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.130 per Nifedipine ER 30 mg tablet, up 19% from $0.109 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Nifedipine ER 30 mg tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Nifedipine 10 mg capsule | Generic | $0.257 per capsule | $7.70 | -19% |
| Nifedipine 20 mg capsule | Generic | $0.686 per capsule | $20.57 | +2% |
| Nifedipine ER 30 mg tablet | Generic | $0.130 per tablet | $3.90 | +19% |
| Nifedipine ER 60 mg tablet | Generic | $0.168 per tablet | $5.04 | +22% |
| Nifedipine ER 90 mg tablet | Generic | $0.269 per tablet | $8.07 | +12% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has nifedipine been recalled?
The FDA's Enforcement Report lists 10 recalls naming nifedipine since 2013: 0 Class I (the most serious), 6 Class II, 4 Class III; 0 still ongoing. 3 of them are by firms that FDA's NDC Directory does not list as a maker of nifedipine and that hold no application for it in Drugs@FDA, such as compounding pharmacies or bulk-ingredient suppliers; the recall notice names the product recalled. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| July 2, 2021 | Class II | The Harvard Drug Group | Failed Dissolution Specification: Out of specification for dissolution during routine stability testing. |
| March 7, 2017 | Class III | Alvogen, Inc | Cross Contamination with another product:residual powder found in inlet air duct identified as sorafenib |
| October 6, 2016 | Class III | Actavis Elizabeth LLC | Presence of Foreign Tablets/Capsules |
| April 17, 2015 | Class II | Valeant Pharmaceuticals North America LLC | Failed Dissolution Specifications: High out of specification dissolution result at 1 hour time point. |
| November 1, 2013 | Class II | Greenstone Llc | Labeling: Incorrect or Missing Lot and/or Exp Date: Greenstone LLC is recalling Nifedipine Extended Release tablets (90mg). … |
| July 2, 2013 | Class II | Aidapak Services, LLC not a listed maker | Labeling: Label Mixup; NIFEDIPINE Capsule, 10 mg may be potentially mislabeled as MULTIVITAMIN/MULTIMINERAL W/FLUORIDE, Chew Tablet, 1 mg (F), NDC 64376081501 … |
| July 2, 2013 | Class II | Aidapak Services, LLC not a listed maker | Labeling:Label Mixup; NIFEdipine, Capsule, 10 mg may be potentially mislabeled as NITROFURANTOIN MONOHYDRATE/ MACROCRYSTALS, Capsule, 100 mg, NDC 47781030301 … |
| July 2, 2013 | Class II | Aidapak Services, LLC not a listed maker | Labeling: Label Mixup: NIFEdipine ER, Tablet, 60 mg may have potentially been mislabeled as the following drug: NICOTINE POLACRILEX, LOZENGE, 2 mg, NDC … |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the nifedipine label say about other medicines?
The nifedipine label names 41 other medicines in its interaction, contraindication or warning sections. The labels of 46 other medicines name nifedipine. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Acarbose | drug interactions | If nifedipine is co-administered with acarbose, blood glucose levels should be monitored carefully and a dose adjustment of nifedipine considered. |
| Azithromycin | drug interactions | CYP3A inhibitors CYP3A inhibitors such as ketoconazole, fluconazole, itraconazole, clarithromycin, erythromycin (Azithromycin, although structurally related to the class of macrolide antibiotic is void of clinically relevant CYP3A4 inhibition), grapefruit, nefazodone, fluoxetine, saquinavir, indinavir, nelfinavir, and … |
| Benazepril | drug interactions | ACE Inhibitors Benazepril: In healthy volunteers receiving single dose of 20 mg nifedipine ER and benazepril 10 mg, the plasma concentrations of benazeprilat and nifedipine in the presence and absence of each other were not statistically significantly different. |
| Candesartan | drug interactions | No significant drug interaction has been reported in studies with candesartan cilexitil given together with nifedipine. |
| Carbamazepine | drug interactions | Strong CYP3A inducers Strong CYP3A inducers, such as rifampin, rifabutin, phenobarbital, phenytoin, carbamazepine, and St. John’s Wort reduce the bioavailability and efficacy of nifedipine; therefore nifedipine should not be used in combination with strong CYP3A inducers such as rifampin (See CONTRAINDICATIONS ). |
| Cimetidine | drug interactions | The C max values of nifedipine in the presence of cimetidine were increased by factors ranging between 1.60 and 2.02. |
| Clarithromycin | drug interactions | CYP3A inhibitors CYP3A inhibitors such as ketoconazole, fluconazole, itraconazole, clarithromycin, erythromycin (Azithromycin, although structurally related to the class of macrolide antibiotic is void of clinically relevant CYP3A4 inhibition), grapefruit, nefazodone, fluoxetine, saquinavir, indinavir, nelfinavir, and … |
| Clopidogrel | drug interactions | Platelet Aggregation Inhibitors Clopidogrel: No clinically significant pharmacodynamic interactions were observed when clopidogrel was co-administered with nifedipine. |
| Digoxin | drug interactions | Digitalis Digoxin: The simultaneous administration of nifedipine and digoxin may lead to reduced clearance resulting in an increase in plasma concentrations of digoxin. |
| Diltiazem | drug interactions | Calcium Channel Blockers Diltiazem: Pre-treatment of healthy volunteers with 30 mg or 90 mg t.i.d. diltiazem p.o. increased the AUC of nifedipine after a single dose of 20 mg nifedipine by factors of 2.2 and 3.1, respectively. |
| Divalproex | drug interactions | Valproic acid may increase the exposure to nifedipine during concomitant therapy. |
| Doxazosin | drug interactions | Co-administration of nifedipine resulted in a decrease in AUC and C max of doxazosin to 83% and 86% of the values in the absence of nifedipine, respectively. |
| Erythromycin | drug interactions | CYP3A inhibitors CYP3A inhibitors such as ketoconazole, fluconazole, itraconazole, clarithromycin, erythromycin (Azithromycin, although structurally related to the class of macrolide antibiotic is void of clinically relevant CYP3A4 inhibition), grapefruit, nefazodone, fluoxetine, saquinavir, indinavir, nelfinavir, and … |
| Fentanyl | warnings | Severe hypotension and/or increased fluid volume requirements have been reported in patients who received immediate release capsules together with a beta-blocking agent and who underwent coronary artery bypass surgery using high dose fentanyl anesthesia. |
Every other medicine the nifedipine label names
| Medicine named | Section | What the label says |
|---|---|---|
| Fluconazole | drug interactions | CYP3A inhibitors CYP3A inhibitors such as ketoconazole, fluconazole, itraconazole, clarithromycin, erythromycin (Azithromycin, although structurally related to the class of macrolide antibiotic is … |
| Fluoxetine | drug interactions | … of clinically relevant CYP3A4 inhibition), grapefruit, nefazodone, fluoxetine, saquinavir, indinavir, nelfinavir, and ritonavir may result in increased exposure to nifedipine when co-administered. |
| Irbesartan | drug interactions | Angiotensin-II Blockers Irbesartan: In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites by nifedipine. |
| Itraconazole | drug interactions | CYP3A inhibitors CYP3A inhibitors such as ketoconazole, fluconazole, itraconazole, clarithromycin, erythromycin (Azithromycin, although structurally related to the class of macrolide antibiotic is … |
| Ketoconazole | drug interactions | CYP3A inhibitors CYP3A inhibitors such as ketoconazole, fluconazole, itraconazole, clarithromycin, erythromycin (Azithromycin, although structurally related to the class of macrolide antibiotic is … |
| Metformin | drug interactions | A single dose metformin-nifedipine interaction study in normal healthy volunteers demonstrated that co-administration of nifedipine increased plasma metformin C max and AUC by 20% and 9% … |
| Miglitol | drug interactions | No effect of miglitol was observed on the pharmacokinetics and pharmacodynamics of nifedipine. |
| Nefazodone | drug interactions | … antibiotic is void of clinically relevant CYP3A4 inhibition), grapefruit, nefazodone, fluoxetine, saquinavir, indinavir, nelfinavir, and ritonavir may result in increased exposure to nifedipine when … |
| Nelfinavir | drug interactions | … inhibition), grapefruit, nefazodone, fluoxetine, saquinavir, indinavir, nelfinavir, and ritonavir may result in increased exposure to nifedipine when co-administered. |
| Omeprazole | drug interactions | Antisecretory Drugs Omeprazole: In healthy volunteers receiving a single dose of 10 mg nifedipine, AUC and C max of nifedipine after pretreatment with omeprazole 20 mg q.d. … |
| Orlistat | drug interactions | Drugs Interfering with Food Absorption Orlistat: In 17 normal-weight subjects receiving orlistat 120 mg t.i.d. for 6 days, orlistat did not alter the bioavailability of 60 mg nifedipine (extended … |
| Pantoprazole | drug interactions | Pantoprazole: In healthy volunteers the exposure to neither drug was changed significantly in the presence of the other drug. |
| Phenobarbital | drug interactions | Strong CYP3A inducers Strong CYP3A inducers, such as rifampin, rifabutin, phenobarbital, phenytoin, carbamazepine, and St. John’s Wort reduce the bioavailability and efficacy of nifedipine; … |
| Phenytoin | drug interactions | Strong CYP3A inducers Strong CYP3A inducers, such as rifampin, rifabutin, phenobarbital, phenytoin, carbamazepine, and St. John’s Wort reduce the bioavailability and efficacy of nifedipine; … |
| Pioglitazone | drug interactions | Glucose Lowering Drugs Pioglitazone: Co-administration of pioglitazone for 7 days with 30 mg nifedipine ER administered orally q.d. … |
| Quinidine | drug interactions | Cardiovascular Drugs Antiarrhythmics Quinidine: Quinidine is a substrate of CYP3A and has been shown to inhibit CYP3A in vitro. |
| Ranitidine | drug interactions | Co-administration of ranitidine did not have relevant effects on the exposure to nifedipine that affected the blood pressure or heart rate in normotensive or hypertensive subjects. |
| Repaglinide | drug interactions | Co-administration of 10 mg nifedipine with a single dose of 2 mg repaglinide (after 4 days nifedipine 10 mg t.i.d. and repaglinide 2 mg t.i.d.) resulted in unchanged AUC and C max values for both … |
| Rifabutin | drug interactions | Strong CYP3A inducers Strong CYP3A inducers, such as rifampin, rifabutin, phenobarbital, phenytoin, carbamazepine, and St. John’s Wort reduce the bioavailability and efficacy of nifedipine; … |
| Rifampin | contraindications | CONTRAINDICATIONS Concomitant administration with strong P450 inducers, such as rifampin, are contraindicated since the efficacy of nifedipine tablets could be significantly reduced. … |
| Ritonavir | drug interactions | … grapefruit, nefazodone, fluoxetine, saquinavir, indinavir, nelfinavir, and ritonavir may result in increased exposure to nifedipine when co-administered. |
| Sirolimus | drug interactions | A single 60 mg dose of nifedipine and a single 10 mg dose of sirolimus oral solution were administered to 24 healthy volunteers. |
| Tacrolimus | drug interactions | Nifedipine has been shown to inhibit the metabolism of tacrolimus in vitro. |
| Timolol | drug interactions | Hypotension is more likely to occur if dihydropryridine calcium antagonists such as nifedipine are co-administered with timolol. |
| Tirofiban | drug interactions | Co-administration of nifedipine did not alter the exposure to tirofiban importantly. |
| Valproic acid | drug interactions | Valproic acid may increase the exposure to nifedipine during concomitant therapy. |
| Verapamil | drug interactions | Verapamil, a CYP3A inhibitor, can inhibit the metabolism of nifedipine and increase the exposure to nifedipine during concomitant therapy. |
Other labels that name nifedipine
Source: FDA drug label (Nifedipine), Aurobindo Pharma Limited, effective December 24, 2024 (SPL set eb70b7ff-f9f0-41d0-901a-f4c04ae9ed46), via openFDA; the full label on DailyMed
What do FAERS reports show for nifedipine?
The FDA Adverse Event Reporting System holds 41,059 reports that list nifedipine among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 4,780 are coded as a death and 17,345 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as nifedipine?
73 other medicines are given the same way (oral) and in the same FDA class as nifedipine or labeled mainly for the same use (high blood pressure), the same class first. High blood pressure lists all 88 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Amlodipine | High blood pressure, Angina | 42 labelers | $0.0102 per tablet 5 mg tablet | No current entry |
| Amlodipine and benazepril | High blood pressure | 16 labelers | $0.114 per unit 10-20 mg | No current entry |
| Amlodipine and atorvastatin | High blood pressure, Angina | 6 labelers | $1.34 per unit 10-40 mg | No current entry |
| Amlodipine and olmesartan | High blood pressure | 14 labelers | $0.248 per unit 10-20 mg | No current entry |
| Felodipine | High blood pressure | 14 labelers | $0.123 per tablet 5 mg tablet | No current entry |
| Amlodipine and hydrochlorothiazide and olmesartan | High blood pressure | 8 labelers | $0.776 per unit 20-5-12.5 | No current entry |
| Amlodipine and valsartan | High blood pressure | 9 labelers | $0.330 per unit 10-160 mg | No current entry |
| Amlodipine and hydrochlorothiazide and valsartan | High blood pressure | 5 labelers | $6.09 per tablet 10-160-25 mg tablet | No current entry |
Every medicine labeled for the same conditions as nifedipine
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does nifedipine compare with medicines for the same use?
19 side-by-side pages set nifedipine beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to nifedipine
- 73 medicines for the same use
- Other calcium channel blockers
- the pharmacologic class, with prices and generics
- Nifedipine side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other